Identification of C-β-D-Glucopyranosyl Azole-Type Inhibitors of Glycogen Phosphorylase That Reduce Glycogenolysis in Hepatocytes: In Silico Design, Synthesis, in Vitro Kinetics, and ex Vivo Studies

被引:13
作者
Barr, Daniel [1 ]
Szennyes, Eszter [2 ]
Bokor, Eva [2 ]
Al-Oanzi, Ziad H. [3 ,7 ]
Moffatt, Colin [4 ]
Kun, Sandor [2 ]
Docsa, Tibor [5 ]
Sipos, Adam [5 ]
Davies, Matthew P. [1 ]
Mathomes, Rachel T. [6 ]
Snape, Timothy J. [6 ]
Agius, Loranne [3 ]
Somsak, Laszlo [2 ]
Hayes, Joseph M. [6 ]
机构
[1] Univ Cent Lancashire, Sch Phys Sci & Comp, Preston PR1 2HE, Lancs, England
[2] Univ Debrecen, Dept Organ Chem, POB 400, H-4002 Debrecen, Hungary
[3] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
[4] De Montfort Univ, Hlth & Life Sci, Gateway House, Leicester LE1 9BH, Leics, England
[5] Univ Debrecen, Dept Med Chem, Med & Hlth Sci Ctr, Egyet Ter 1, H-4032 Debrecen, Hungary
[6] Univ Cent Lancashire, Sch Pharm & Biomed Sci, Preston PR1 2HE, Lancs, England
[7] Aljouf Univ, Med Lab Sci, Sakaka, Saudi Arabia
关键词
GLUCOSE ANALOG INHIBITORS; SPIRO-THIOHYDANTOIN; DERIVATIVES; METABOLISM; TARGETS;
D O I
10.1021/acschembio.9b00172
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Several C-beta-D-glucopyranosyl azoles have recently been uncovered as among the most potent glycogen phosphorylase (GP) catalytic site inhibitors discovered to date. Toward further exploring their translational potential, ex vivo experiments have been performed for their effectiveness in reduction of glycogenolysis in hepatocytes. New compounds for these experiments were predicted in silico where, for the first time, effective ranking of GP catalytic site inhibitor potencies using the molecular mechanics-generalized Born surface area (MM-GBSA) method has been demonstrated. For a congeneric training set of 27 ligands, excellent statistics in terms of Pearson (R-P) and Spearman (R-s) correlations (both 0.98), predictive index (PI = 0.99), and area under the receiver operating characteristic curve (AU-ROC = 0.99) for predicted versus experimental binding affinities were obtained, with ligand tautomeric/ionization states additionally considered using density functional theory (DFT). Seven 2-aryl-4(5)-(beta-D-glucopyranosyl)-imidazoles and 2-aryl-4(beta-D-glucopyranosyl)-thiazoles were subsequently synthesized, and kinetics experiments against rabbit muscle GPb revealed new potent inhibitors with best K-i values in the low micromolar range (5c = 1.97 mu M; 13b = 4.58 mu M). Ten C-beta-D-glucopyranosyl azoles were then tested ex vivo in mouse primary hepatocytes. Four of these (5a-c and 9d) demonstrated significant reduction of glucagon stimulated glycogenolysis (IC50 = 30-60 mu M). Structural and predicted physicochemical properties associated with their effectiveness were analyzed with permeability related parameters identified as crucial factors. The most effective ligand series 5 contained an imidazole ring, and the calculated pK(a) (Epik: 6.2; Jaguar 5.5) for protonated imidazole suggests that cellular permeation through the neutral state is favored, while within the cell, there is predicted more favorable binding to GP in the protonated form.
引用
收藏
页码:1460 / 1470
页数:11
相关论文
共 49 条
[1]   Role of glycogen phosphorylase in liver glycogen metabolism [J].
Agius, Loranne .
MOLECULAR ASPECTS OF MEDICINE, 2015, 46 :34-45
[2]   Glucose 6-phosphate causes translocation of phosphorylase in hepatocytes and inactivates the enzyme synergistically with glucose [J].
Aiston, S ;
Green, A ;
Mukhtar, M ;
Agius, L .
BIOCHEMICAL JOURNAL, 2004, 377 :195-204
[3]   Glucose 6-phosphate regulates hepatic glycogenolysis through inactivation of phosphorylase [J].
Aiston, S ;
Andersen, B ;
Agius, L .
DIABETES, 2003, 52 (06) :1333-1339
[4]   Inhibition of glycogenolysis in primary rat hepatocytes by 1,4-dideoxy-1,4-imino-d-arabinitol [J].
Andersen, B ;
Rassov, A ;
Westergaard, N ;
Lundgren, K .
BIOCHEMICAL JOURNAL, 1999, 342 :545-550
[5]  
[Anonymous], 2016, SMALL MOL DRUG DISC
[6]   Computationally motivated synthesis and enzyme kinetic evaluation of N-(β-D-glucopyranosyl)-1,2,4-triazolecarboxamides as glycogen phosphorylase inhibitors [J].
Begum, Jaida ;
Varga, Gergely ;
Docsa, Tibor ;
Gergely, Pal ;
Hayes, Joseph M. ;
Juhasz, Laszlo ;
Somsak, Laszlo .
MEDCHEMCOMM, 2015, 6 (01) :80-89
[7]   C-Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential [J].
Bokor, Eva ;
Kun, Sandor ;
Goyard, David ;
Toth, Marietta ;
Praly, Jean-Pierre ;
Vidal, Sebastien ;
Somsak, Laszlo .
CHEMICAL REVIEWS, 2017, 117 (03) :1687-1764
[8]   4(5)-Aryl-2-C-glucopyranosyl-imidazoles as New Nanomolar Glucose Analogue Inhibitors of Glycogen Phosphorylase [J].
Bokor, Eva ;
Kun, Sandor ;
Docsa, Tibor ;
Gergely, Pal ;
Somsak, Laszlo .
ACS MEDICINAL CHEMISTRY LETTERS, 2015, 6 (12) :1215-1219
[9]   Specific features of glycogen metabolism in the liver [J].
Bollen, M ;
Keppens, S ;
Stalmans, W .
BIOCHEMICAL JOURNAL, 1998, 336 :19-31
[10]   IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding [J].
Cer, R. Z. ;
Mudunuri, U. ;
Stephens, R. ;
Lebeda, F. J. .
NUCLEIC ACIDS RESEARCH, 2009, 37 :W441-W445